Chronic hepatitis C virus (HCV) infection is an established cause of liver cancer, and recent studies have suggested a link with kidney cancer. The aim of this study was to evaluate risk of kidney cancer in relation to HCV infection in a nationwide registry-based study of Swedish residents diagnosed with HCV between 1990 and 2006. A total of 43 000 individuals with chronic HCV infection were included, and the mean follow-up time was 9.3 years. Observed kidney cancer incidence and mortality in the cohort were compared with expected values based on the age-adjusted and sex-adjusted rates in the general population. Risk of hospitalization for other chronic kidney disease was also evaluated using Cox proportional hazards regression. No association between HCV infection and risk of kidney cancer was observed [standardized incidence ratio with 1-year lag = 1.2; 95% confidence interval (CI): 0.8-1.7]. Risk of hospitalization for noncancer kidney disease was significantly elevated in the HCV cohort, with significantly stronger associations observed among women than among men [hazard ratio = 5.8 (95% CI: 4.2-7.9) and 3.9 (95% CI: 3.2-4.8) for women and men, respectively]. Results of this study do not support the hypothesis that chronic HCV infection confers an increased risk of kidney cancer. However, we did find an association between HCV infection and chronic kidney disease, particularly among women. Given inconsistent findings in the literature, it is premature to consider HCV infection to be a risk factor for kidney cancer.
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Introduction
Approximately 170 million people throughout the world are chronically infected with hepatitis C virus (HCV) (Poynard et al., 2003; Lavanchy, 2009) . Chronic HCV infection has been recognized as a major cause of liver cancer (London and McGlynn, 2006) and has been consistently associated with increased risk of non-Hodgkin lymphoma (Duberg et al., 2005; Dal Maso and Franceschi, 2006) . HCV infection is also associated with chronic renal disease (Meyers et al., 2003; Perico et al., 2009) , and HCV-RNA and HCV proteins have been isolated from kidney tissues of HCV-infected individuals with various forms of glomerulonephritis (Sansonno et al., 2005; Cao et al., 2009) . In a nationwide register-based cohort of all Swedish residents diagnosed with HCV infection, risk of death due to kidney cancer was significantly elevated . A more recent epidemiologic study by Gordon et al. (2010) reported increased incidence of kidney cancer among HCV-infected individuals.
To follow-up on earlier findings of increased kidney cancer mortality in a cohort of HCV-infected residents of Sweden, we carried out an analysis of kidney cancer incidence in this population. Since the earlier mortality study, an additional 7164 HCV-infected individuals were added to the cohort and follow-up was extended through 2008, thus almost doubling the total observation time to include over 400 000 person-years. As a secondary analysis, we have also evaluated the risk of hospitalization for chronic kidney disease in relation to HCV infection.
Materials and methods

Study population
Enumeration of the HCV cohort has been described earlier . In brief, records of all residents of Sweden who were notified with HCV infection between 1990 and 2006 were extracted from the national surveillance database at the Swedish Institute for Infectious Disease Control (SMI). Both the diagnosing laboratory and the clinician are required to report HCV infections to the SMI, and the SMI database includes information of epidemiologic interest such as date of HCV notification and suspected route of transmission. The sensitivity of this reporting system is high (> 98% in 2002 for notifiable infections studied so far) (Jansson et al., 2005) . As unique personal identification numbers (available for all Swedish residents) were needed for linkage with other registers, HCV records without complete identification numbers (N = 623) were excluded from this analysis. Six additional individuals with conflicting data (e.g. deaths before HCV notification) were also excluded. After these exclusions, a total of 43 000 individuals remained in the HCV-infected cohort for this analysis.
To evaluate kidney conditions other than cancer, we compared the risk of chronic kidney disease in the HCVinfected cohort with that of a non-HCV-infected cohort selected from the general population and matched for year of birth, sex, and county of residence in Sweden. Five individuals who were never diagnosed with HCV infection were matched to each HCV-infected individual, resulting in a cohort of 215 000 individuals not diagnosed with HCV. To avoid selection bias, individuals were excluded from these analyses if they had ever been hospitalized with kidney disease as the principal diagnosis from 1969 until 1 year after HCV notification. For non-HCV-infected individuals, the corresponding reference date is equivalent to the date of HCV notification for the matched HCV-infected individual. Individuals who were hospitalized for any condition in the year before HCV notification were also excluded, leaving 25 412 HCV-infected individuals and 198 124 individuals never diagnosed with HCV in these analyses.
Linkage to other registers
Records from the SMI register were linked with several other national registers for this study. The Swedish Population register maintained by Statistics Sweden was used to identify the matched noninfected cohort and to obtain information on dates of immigration, emigration, or death. The National Board of Health and Welfare added information from the national Cancer, Cause of Death and Hospital Discharge registers. Incident cases of kidney cancer were identified through the Cancer register; case ascertainment in this register is very high (95% of detected cancers), and nearly all (99%) reported cases are histologically or cytologically confirmed (Mattson, 1984) . Cancer diagnoses were coded using the seventh revision of the ICD. We extracted information on incident kidney cancer cases (excluding cases of renal pelvis cancer) diagnosed between 1990 and 2008 (ICD-7 codes: 180.0 and 180.9). Histologic confirmation was available for all of the kidney cancer cases in the HCVinfected cohort. One kidney tumor was benign and excluded from these analyses. The 25 individuals with kidney cancer diagnosed before HCV notification were excluded. Individuals who were diagnosed with other types of cancer were not excluded from the study cohort or from the population incidence rates. Only one of the kidney cancer cases in the HCV-infected cohort had been diagnosed earlier with another cancer. We also extracted information from the Cause of Death register on kidney cancer mortality (listed as the underlying cause of death) between 1990 and 2007, the last year for which these data were available (1990 ( -1997 1998 -2007 , ICD-10 code: C64).
Data on hospitalization discharge diagnoses were extracted from the Hospital Discharge register, which started in 1964 and since 1987 has covered all inpatient care in Sweden. Secondary analyses were carried out to evaluate risk of inpatient hospitalization for treatment of the following chronic kidney diseases from 1990 to 2008: (i) glomerular diseases (ICD-9 codes: 580-583, ICD-10 codes: N00-N08), (ii) renal failure (ICD-9 codes: 584-586, ICD-10 codes: N17-N19), and (iii) other kidney diseases (ICD-9 codes: 587-589 and 593, ICD-10 codes: N25-N28). Events were defined as the first hospitalization per individual for which each of the aforementioned conditions was listed as the principal diagnosis code.
Statistical analysis
The kidney cancer risk in the HCV-infected cohort was expressed as standardized incidence ratios (SIRs) calculated by dividing the number of observed kidney cancers by the expected number. To calculate the expected number of cancers, we used sex-specific, age-specific, and calendar year-specific incidence rates from the general population in Sweden multiplied by the number of personyears within each stratum in the HCV-infected cohort. Observation time began on the date of HCV notification and ended at the time of kidney cancer diagnosis, death, emigration (available through 2007 only), or 31 December 2008, whichever came first (total of 400 196 person-years). To evaluate potential effects of selection bias on risk estimates, analyses were carried out using various lag periods after HCV notification (none up to 2 years) for the start of follow-up and calculation of person-years. Stratified analyses were carried out by sex, estimated duration of HCV infection, and year of birth. Estimated duration of HCV infection was characterized by using an earlier developed model based on age, suspected route of transmission, and the epidemiology of HCV transmission in Sweden (Strauss et al., 2008) . We also evaluated the relative risk of death due to kidney cancer in relation to HCV infection by calculating standardized mortality ratios (SMRs) using the same methods as described above. Exact 95% confidence intervals (CIs) for the SIRs and SMRs were calculated assuming a Poisson distribution for the observed number of cases and deaths.
For the analyses of chronic kidney disease in relation to HCV infection, we used Cox proportional hazards regression to evaluate time until first hospitalization for chronic 327 kidney disease in the HCV-infected cohort relative to the non-HCV-infected cohort as described above. Follow-up began 1 year after HCV notification (or the corresponding date for non-HCV-infected individuals). The Cox regression models included terms for HCV status, age, sex, and interaction between HCV status and sex. Plots of the hazard functions were evaluated to confirm that the proportional hazards assumption was appropriate. Analyses were repeated after excluding 2584 HCV-infected individuals for whom the suspected route of HCV transmission was through transfusion of blood or blood products or nosocomial infection to assess potential bias due to reverse causation (i.e. HCV infection resulting from treatment for chronic kidney disease).
Statistical analyses were carried out using SAS Software, V9.1 (SAS Institute, Cary, North Carolina, USA). Results were considered to be statistically significant if P values were less than 0.05.
Ethics and confidentiality
All study procedures were approved by the Regional Ethical Review Board in Stockholm, Sweden. After performing the record linkages, the personal identification numbers were deleted before analysis to ensure confidentiality of the data set.
Results
Demographic and other characteristics of HCV-infected individuals are reported in Table 1 . Most HCV-infected individuals were male (69%), and median age at HCV notification was 37.6 years. The most common suspected route of HCV transmission was intravenous drug use (58%).
Although we observed a slight increased incidence of kidney cancer among HCV-infected individuals, overall, this association was reduced to an insignificant level with 3-month and 1-year lag periods (Table 2) . Results were similar after restricting to adenocarcinomas only (SIR with a 1-year lag period = 1.1, 95% CI: 0.7-1.6; 26 observed cases in the HCV-infected cohort). Stratified analyses showed minor differences by sex [SIR = 1.3 (95% CI: 0.5-2.7) and 1.1 (95% CI: 0.7-1.7) for women and men, respectively], and higher SIRs among individuals with an estimated duration of HCV infection of 20 years or less (SIR = 1.9, 95% CI: 1.0-3.2) and among individuals born after 1959 (SIR = 1.7, 95% CI: 0.6-3.7). We did not see an association between chronic HCV infection and kidney cancer mortality in an analysis with a 2-year lag period (SMR = 1.2, 95% CI: 0.6-2.2; 11 observed deaths in the HCV-infected cohort).
Chronic HCV infection was associated with a significantly increased risk of hospitalization for other noncancer kidney diseases (Table 3) . Risk of all noncancer kidney diseases differed significantly by sex (P interaction = 0.045). Hazard ratios of 3.9 (95% CI: 3.2-4.8) and 5.8 (95% CI: 4.2-7.9) were observed among men and women, respectively. Among men, risk estimates ranged from 2.9 (95% CI: 2.0-4.3) for glomerular diseases to 4.6 (95% CI: 3.7-5.8) for renal failure. Among women, risk estimates ranged from 5.1 (95% CI: 3.0-8.8) for glomerular diseases to 10.0 (95% CI: 2.7-37.2) for other noncancer kidney diseases. For all Cox regression analyses, we observed similar risk estimates after excluding individuals for whom the suspected route of HCV transmission was through transfusion of blood or blood products or nosocomial infection (data not shown).
Discussion
Overall, the findings of this study do not support the hypothesis that chronic HCV infection confers an increased risk of kidney cancer. After accounting for potential selection bias in lagged analyses, we did not observe associations between HCV infection and risk of kidney cancer.
The borderline significant increase in the SIR among individuals with shorter estimated duration of HCV infection but not among individuals with longer duration of HCV infection is contrary to expectations. This association may be driven by age-related differences in kidney cancer risk (age is highly correlated with estimated duration of HCV infection) or by frailty (i.e. greater susceptibility to kidney cancer development early in the course of infection, and thus decreasing risk for the remaining population with continued follow-up time). This finding may also be due to chance given the small number of expected cases in the stratum with shorter duration of HCV infection.
Associations between chronic HCV infection and kidney cancer have been reported earlier, though results are somewhat inconsistent. An earlier analysis of kidney cancer mortality among Swedish residents infected with HCV found a statistically significant increased risk compared with the general population . In our more recent analysis of kidney cancer mortality, which had a longer lag period (2 years vs. 6 months), and included 7164 additional HCV-infected individuals and added four years of follow-up, we were unable to confirm this association. In another recent study of 3057 HCV-infected individuals, identified through an administrative database from a large integrated healthcare system, Gordon et al. (2010) reported a 77% increased risk of renal cell carcinoma incidence among HCV-positive individuals relative to HCV-negative individuals (N = 17 cases of renal cell carcinoma among HCV-infected individuals). However, a community-based linkage study of 75 834 HCV-infected individuals in Australia found no association with kidney cancer incidence (N = 18 cases of kidney cancer among HCVinfected subjects) (Amin et al., 2006) .
Although we did not see an association between HCV infection status and risk of kidney cancer, we did observe strong, statistically significant associations with other chronic kidney disease. These findings are consistent with earlier evidence of an increased risk of noncancer kidney disease among HCV-infected individuals (Meyers et al., 2003; Tsui et al., 2007; Perico et al., 2009) . The consistency of these findings with results of earlier studies of chronic renal disease other than cancer provides further support for the validity of these data.
We also observed stronger associations between HCV infection and noncancer kidney disease among women than among men, which, to our knowledge, is a novel finding and should be confirmed in future studies.
Although the HCV-related relative risk of kidney disease was greater for women than men, the background rates of kidney diseases were lower among women than among men in the reference population of Swedish residents, which is consistent with differences by sex in risk of endstage renal disease observed in other populations (Iseki, 2008) . Consequently, although these data indicate a stronger association between HCV infection and kidney disease among women than among men, the absolute risk of HCV-related kidney disease may not necessarily differ by sex. Differences in HCV-related kidney disease pathogenesis by sex could possibly be attributable to underlying biological characteristics (Carrero, 2010) , and further studies are needed to confirm these findings.
Strengths and limitations
This population-based study used nationwide register data in Sweden between 1990 and 2008. With a total of 43 000 HCV-infected subjects and a mean follow-up of 9.3 years, this study is, to our knowledge, the largest investigation of HCV infection and kidney cancer to date in terms of person-years of observation. Another strength is the national system with personal identification numbers, which enables the linkage with other national registers and allows the assessment of individual risk over time. The nationwide communicable disease register at SMI has high sensitivity; among the 215 000 individuals in the reference population, there were only seven admissions (of 216 047) related to HCV infection that were not captured in the SMI database. The Cancer Registry also has high sensitivity, and all of the kidney cancer cases included in this analysis were histologically confirmed.
The possibility of selection bias is a limitation of this study. To address this limitation, we used the cumulative SIR method (Torner et al., 2010) and calculated SIRs with varying lag times (none up to 2 years). Exclusion of additional cases and person-time beyond a 1-year lag period did not change the estimated SIR. As treatment of end-stage renal disease may involve blood transfusions and hemodialysis, which are potential risk factors for HCV transmission, reverse causation bias was a potential concern in the analyses of hospitalizations for noncancer kidney diseases. However, the impact of this type of bias on the reported results is likely to be minimal because all individuals with earlier diagnoses of kidney diseases since 1969 were excluded from these analyses, and risk estimates were similar after excluding individuals for whom transfusion of blood/blood products or nosocomial infection was the suspected route of HCV transmission.
Finally, data on known risk factors for kidney cancer (e.g. smoking status, obesity) (Chow et al., 2010) were unavailable for adjustment. However, it is unlikely that the uncontrolled confounding would lead to both the null results for HCV infection and kidney cancer and a positive association for HCV infection and chronic kidney disease. The association with chronic kidney disease observed in our study is consistent with earlier studies, which lends credence to our findings.
Conclusion
The results of this nationwide register-based study of residents of Sweden do not support the hypothesis that HCV-infected individuals are at an increased risk of developing kidney cancer. However, this study adds to the evidence that HCV infection confers an increased risk of noncancer chronic kidney disease, particularly among women; further investigation of these apparent differences by sex is warranted.
